Introduction
Multiple myeloma, bone marrow malignancy, haematologic cancers, MM
MULTIPLE MYELOMA, SOLID TUMOUR
Multiple myeloma (MM) is a bone marrow malignancy accounting for almost 10% of all haematologic cancers [Assessment of patient response to therapy is an important element when determining appropriate treatments for MM [The use of real-world data (RWD) is key to understanding the treatment course of patients with MM in clinical practice and the impact of novel treatments on all patients with MM, in particular those not eligible for or not reached by clinical trials. However, in routine clinical practice, the treatment responses recorded in patients’ medical records are often not standardized. Although some studies (in treated solid tumours) have shown that response rates can be successfully extracted from medical notes and radiologic reports stored in electronic health records (EHRs), they have also been reported to be overestimated [To overcome the issue of missing data, we proposed a real-world derived response (dR) algorithm adapted from IMWG response criteria (‘flexible’ IMWG) that is able to estimate the response of patients with MM using less stringent criteria [